Adult HTN & angina Initially 5 mg once daily, may be increased to a max dose of 10 mg depending on individual patient's response. Paed patient 6-17 yrHTN Initially 2.5 mg once daily, up-titrated to 5 mg once daily if BP goal is not achieved after 4 wk.
Administration
May be taken with or without food.
Contraindications
Hypersensitivity to amlodipine or to dihydropyridine derivatives. Severe hypotension; shock (including cardiogenic shock); obstruction of the outflow tract of the left ventricle (eg, high grade aortic stenosis); haemodynamically unstable heart failure after acute MI.
Special Precautions
Patients w/ heart failure; hepatic impairment; elderly. Minor or moderate influence on the ability to drive & use machines. Safety & efficacy in hypertensive crisis has not been established. Pregnancy & lactation.
Increased risk of hypotension w/ strong or moderate CYP3A4 inhibitors (eg, PIs, azole antifungals, macrolides like erythromycin or clarithromycin, verapamil or diltiazem). Increased bioavailability w/ grapefruit or grapefruit juice. Varied effect on plasma conc w/ CYP3A4 inducers (eg, rifampicin, Hypericum perforatum). Due to risk of hyperkalaemia, avoid co-administration of Ca channel blockers in patients susceptible to malignant hyperthermia & in the management of malignant hyperthermia (dantrolene infusion). Additive effect w/ other antihypertensives. Increased exposure of simvastatin. Risk of increased blood levels of tacrolimus. May increase exposure of mTOR inhibitors. Increased trough conc of ciclosporin in renal transplant patients.
C08CA01 - amlodipine ; Belongs to the class of dihydropyridine derivative selective calcium-channel blockers with mainly vascular effects. Used in the treatment of cardiovascular diseases.
Sign Out
